Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from preserved prostaglandin eye drops to preservative‑free tafluprost and effect on tear film thickness in glaucoma/ocular hypertension
2015-004012-37Phase 4Completed
- Sponsor
- Ordination Dr. Andreas Hommer
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Ordination Dr. Andreas Hommer. Primary endpoint: Tear film thickness at end of treatment. Started Nov 2015; status: completed.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2015-004012-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004012-37.